X

Drug Profile

Rilmakalim

Alternative Names: HOE 234; Rimalkalim

Latest Information Update: 26 Jul 2002

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Aventis
Class Antiasthmatics; Antihypertensives; Bronchodilators; Chromans; Pyrrolidines; Small molecules
Mechanism of Action KATP channel stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Asthma; Coronary disorders

Most Recent Events

19 Apr 2000 Discontinued-I for Asthma in Germany (unspecified route)
01 Nov 1996 A preclinical study has been added to the Obstructive Airways Disease pharmacodynamics section
16 Mar 1995 Discontinued-Unspecified Phase in Coronary disorders in Germany (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com